Banner

May 13, 2008

Guest: Anthony Costello

Clinical Data in 2017

The burden of day-to-day responsibilities does not always allow for appropriate reflection on the future. 

Guest: Carol Rozwell

The Case For Standards Now

Gartner’s Carol Rozwell is one of the industry’s leading authorities on technology adoption and clinical data standards. 

Register Now!
ClinPage members can listen to full-length podcasts and download podcast transcripts.
Login





Forgot your password?
Guest: Anthony Costello

Clinical Data in 2017

February 14, 2008
LENGTH: 9:00

The burden of day-to-day responsibilities does not always allow for appropriate reflection on the future. The Society for Clinical Data Management is trying to address that next month in its annual Leadership Forum. Held in Durham this year, it’s for senior-level executives. Space is limited. It’s an intimate, forward-looking gathering intended to allow peers to discuss what they’re grappling with in depth.

This year’s event has been reformatted to have more access to industry thought leaders and FDA officials who will be charting the future of clinical data for the next ten years. All of the presentations at the Forum will be conducted in an intimate, free-form manner to faciitate in-depth discussions between peers. 

In this podcast, Anthony Costello, a past chair of the SCDM and a co-founder of Nextrials, discusses some of the highlights for this year’s meeting, including a peek at CDISC’s CDASH forms and an update on a promising integration of electronic health records and 21 CFR Part 11-compliant systems for clinical trials. the agenda for the meeting.

In talking with Costello, it’s clear the SCDM wants to have this be a meeting that helps attendees be ready for the long-term future that awaits them. Here’s how Costello put it: “We don’t just mean next year. We mean the next several years. Where will data management go? Where will clinical trials go? Where especially is technology going, because it’s changing so quickly? And how can we get the best and the brightest people in the room and really think about how our industry is going to change over the next five or 10 years?”

There are several high level FDA speakers on the agenda of the meeting, including Rachel Behrman. We asked Costello about that. “Obviously, FDA created the Critical Path initiative to be a leader in this space. So it just makes sense to have the leaders from the regulatory body participating in an open forum like this with the leaders from the industry.”